Relevant bibliographies by topics / Gcb-Dlbcl

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Book chapters
  4. Conference papers

Academic literature on the topic 'Gcb-Dlbcl'

Author: Grafiati
Published: 7 July 2024
Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Gcb-Dlbcl.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Gcb-Dlbcl"

1

Pukiat, Sulada, Nuttapong Ngamphaiboon, Pooja Advani, et al. "BCL-2 Expression at the Time of Diagnosis Affects the Clinical Outcome of Patients with Germinal Center and Non-Germinal Center Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Chemo-Immunotherpy." Blood 116, no. 21 (2010): 3130. http://dx.doi.org/10.1182/blood.v116.21.3130.3130.

Full text
Abstract:
Abstract Abstract 3130 DLBCL has been recognized as a heterogeneous disease varying in molecular biology and clinical outcome. The use of genetic expression profiling has led to the sub-classification of DLBCL into germinal center B-cell like (GCB) and non-germinal center B cell like (non-GCB) based on the cell of origin of the neoplastic B-cell. Immunohistochemistry (IHC) algorithms had been developed and validated to identify GCB or non-GCB DLBCL. Deregulation of Bcl-2 family member of proteins plays an important role in the development, progression, and prognosis of various subtypes of B-ce
APA, Harvard, Vancouver, ISO, and other styles
2

Tarius, Jenifer Marsela, Hermawan Istiadi, Ika Pawitra Miranti, and Intan Rahmania Eka Dini. "THE CORRELATION BETWEEN CELL OF ORIGIN SUBTYPE WITH OVERALL SURVIVAL OF DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS IN KARIADI GENERAL HOSPITAL SEMARANG." DIPONEGORO MEDICAL JOURNAL (JURNAL KEDOKTERAN DIPONEGORO) 9, no. 3 (2020): 252–58. http://dx.doi.org/10.14710/dmj.v9i3.27504.

Full text
Abstract:
Background: DLBCL is the most common type of NHL in the world. DLBCL based on cell of origin is divided into GCB and non-GCB. The diagnosis of DLBCL has not been routinely done to its cell of origin, and there have not been many studies that discuss the DLBCL subtype and the overall survival of the patients, especially in Kariadi General Hospital. This study aims to determine the correlation of DLBCL cell of origin with the 2-year overall survival of DLBCL patients in Kariadi General Hospital. Methods: This is an observational analytic study of 40 DLBCL patients in Kariadi General Hospital fro
APA, Harvard, Vancouver, ISO, and other styles
3

Gandhi, Shipra, Vishala T. Neppalli, George Deeb, Myron S. Czuczman, and Francisco J. Hernandez-Ilizaliturri. "Distinct CD30 Expression Patterns In Germinal Center B-Cell (GCB) and Non-GCB Diffuse Large B-Cell Lymphoma (DLBCL)." Blood 122, no. 21 (2013): 5064. http://dx.doi.org/10.1182/blood.v122.21.5064.5064.

Full text
Abstract:
Abstract Background DLBCL is the most common type of non-Hodgkin lymphoma, which demonstrates morphologic, immunophenotypic, molecular, and clinical heterogeneity. Gene expression profiling studies define two molecular subtypes of DLBCL, namely germinal center B-cell-like (GCB) and activated B-cell-like (ABC) DLBCL. Hans' algorithm was developed to provide an immunohistochemical correlation to the molecular subtypes of DLBCL. In the pre and post-rituximab era, ABC subtype of DLBCL is known to demonstrate poor overall survival when compared to GCB subtype. In addition, relapsed or primary refra
APA, Harvard, Vancouver, ISO, and other styles
4

Hayama, Miyuki, Masataka Okamoto, Yuki Hagiwara, et al. "Clinical Significance of Immunohistochemical Markers of Diffuse Large B-Cell Lymphoma In the Rituximab Era." Blood 116, no. 21 (2010): 1800. http://dx.doi.org/10.1182/blood.v116.21.1800.1800.

Full text
Abstract:
Abstract Abstract 1800 Rituximab combination chemotherapy has significantly improved the treatment outcome of diffuse large B-cell lymphoma (DLBCL). Therefore, the prognostic factors of DLBCL in the rituximab era are different from previously reported prognostic factors. Biological prognostic markers have been analyzed to help understand the biologic basis of treatment outcome. Hans, et al. reported that patients with non-germinal center B-cell like (GCB)-type DLBCL had a significantly poorer prognosis than those with GCB-type DLBCL in the pre-rituximab era. In patients who received rituximab
APA, Harvard, Vancouver, ISO, and other styles
5

Kharchenko, Yevgeniya, Tatyana Semiglazova, Anna Artemeva, et al. "PROGNOSTIC IMPACT OF IMMUNOHISTOCHEMICAL AND MOLECULAR GENETIC MARKERS IN DIFFUSE LARGE B-CELL LYMPHOMA." Problems in oncology 66, no. 1 (2020): 79–89. http://dx.doi.org/10.37469/0507-3758-2020-66-1-79-89.

Full text
Abstract:
Aim: To identify incidence and prognostic impact of different IHC and molecular genetic markers in Diffuse Large B-cell lymphoma. Methods: We analyzed 215 patients with DLBCL who received treatment from 2008 to 2016. We assess expression of different IHC markers, defined DLBCL to GCB and non-GCB subtypes by Hans-algorithm and performed FISH to evaluate MyC, BcL2 and BCL6 translocations. Results: Median follow-up was 29 months. Non-GCB DLBCL were identified in 44 pts (62,9%), GCB-subtype in 26 pts (37,1%). Median PFS in non-GCB DlBCL was 46,0 months, in GCB DLBCL median PFS and 75% quartile was
APA, Harvard, Vancouver, ISO, and other styles
6

Adhi Pangarsa, Eko, Desta Nur Ewika Ardini, Daniel Rizky та ін. "The association of Hypoxia-Inducible Factor-2α (HIF-2α) overexpression score with Germinal Center B-Cell Like (GCB) and Non-Germinal Center B-Cell Like (Non-GCB) subtypes of Diffuse Large B-cell Lymphoma (DLBCL)". Bali Medical Journal 12, № 3 (2023): 2456–62. http://dx.doi.org/10.15562/bmj.v12i3.4521.

Full text
Abstract:
Link of Video Abstract: https://www.youtube.com/watch?v=KF58IGGdWmc Background: Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin's lymphoma. It is classified into homogeneous subtypes, namely Germinal Center B-Cell Like (GCB) and Non-Germinal Center B-Cell Like (GCB), with the latter associated with worse survival outcomes. Increased expression of Hypoxia-Inducible Factor-2α (HIF-2α) is often observed in DLBCL and has been correlated with enhanced angiogenesis, suggesting its potential as a prognostic factor in managing DLBCL. The study evaluates the association bet
APA, Harvard, Vancouver, ISO, and other styles
7

Mishima, Yuko, Masahiro Yokoyama, Noriko Nishimura, et al. "R-CHOP Therapy Cannot Overcome CD5 Positive Non-GCB Subtype of DLBCL." Blood 126, no. 23 (2015): 1507. http://dx.doi.org/10.1182/blood.v126.23.1507.1507.

Full text
Abstract:
Abstract Introduction: There are various poor prognosis factors in diffuse large B cell lymphoma (DLBCL). CD5 positive (CD5+) is estimated as one of the poor prognosis markers in DLBCL. CD5+ DLBCL is completely distinguished from CLL or Mantle cell lymphoma, and de Novo CD5+ DLBCL is related to a high incidence of cytogenetic abnormalities of 8p21 and 11q13. In many cases, CD5+ DLBCL is associated with an aggressive clinical status and advanced stages. Several chromosomal studies have demonstrated the gene expression was similar to non-GCB type of DLBCL. In the clinical phase, it is easy to ex
APA, Harvard, Vancouver, ISO, and other styles
8

Chavez, Julio, Mark Walsh, Francisco J. Hernandez-Ilizaliturri, Anjana Elefante, and Myron S. Czuczman. "Classification of Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) According to the Han's Criteria Defines Two Groups of Patients with Different Clinical Outcomes Following Systemic Rituximab-Multi Agent Anthracycline-Based Therapy." Blood 114, no. 22 (2009): 623. http://dx.doi.org/10.1182/blood.v114.22.623.623.

Full text
Abstract:
Abstract Abstract 623 Gene expression profiling has successfully distinguished three subtypes of DLBCL with different biology and response to treatment: 1) germinal center B-cell (GCB); and 2) non-germinal center lymphomas, that include: activated B-cell-like (ABC) and Type 3 subtypes. Currently, immunohistochemical (IHC) analysis of lymphoma biopsy specimens appear to be a more widely applicable methodology (i.e. compared to gene microarray analysis) to use in order to differentiate between subtypes of DLBCL. While the clinical benefit of adding rituximab to CHOP or CHOP-like chemotherapy as
APA, Harvard, Vancouver, ISO, and other styles
9

Van Meerten, Tom, Renee Bouwstra, Yuan He, et al. "CD47 Expression Defines the Efficacy of Rituximab in Non-Germinal Center B-Cell (non-GCB) Diffuse Large B-Cell Lymphoma (DLBCL)." Blood 132, Supplement 1 (2018): 2852. http://dx.doi.org/10.1182/blood-2018-99-114561.

Full text
Abstract:
Abstract CD47 is an immune-checkpoint protein that binds SIRPa on immune cells to deliver an inhibitory "don't eat me" signal. CD47 is a prominent new target in B-cell malignancies, in which CD47 antibody in combination with the CD20 antibody rituximab (R) is explored in clinical trials. Addition of R to CHOP chemotherapy significantly improves survival of patients with DLBCL, but how CD47 expression contributes to this positive impact of R on patient outcome is currently unclear. Especially in the context of the different cell-of-origin DLBCL subtypes (Germinal Center B-cell (GCB) vs non-GCB
APA, Harvard, Vancouver, ISO, and other styles
10

Niitsu, Nozomi, Naoki Takahashi, Tadashi Yoshino, Masataka Okamoto, and Shigeo Nakamura. "Prognostic Significance of EBV Association in Diffuse Large B-Cell Lymphoma in the Rituximab Era." Blood 126, no. 23 (2015): 3911. http://dx.doi.org/10.1182/blood.v126.23.3911.3911.

Full text
Abstract:
Abstract Introduction: Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous group of diseases in terms of morphology, immunohistochemistry and molecular features. The prognostic factors of DLBCL in the rituximab era are different from previously reported prognostic factors. Hans, et al. reported that patients with non-germinal center B-cell like (GCB)-type DLBCL had a significantly poorer prognosis than those with GCB-type DLBCL in the pre-rituximab era. In patients who received rituximab combination chemotherapy, there is a report that did not find a difference in survival ratio between t
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Gcb-Dlbcl"

1

Prévaud, Léa. "Rôle de la sous-unité c-Rel NFkB dans les Lymphômes B Diffus à Grandes Cellules du Centre Germinatif (GCB-DLBCLs) : établissement d'un modèle murin préclinique." Electronic Thesis or Diss., Limoges, 2023. http://www.theses.fr/2023LIMO0108.

Full text
Abstract:
Le facteur de transcription Rel/NF-kB inclut 5 sous-unités (SU), p50, p52, c-Rel, RelA et RelB qui s'associent en dimères. NF-κB est au cœur de l'ontogénie des lymphocytes B matures dans les centres germinatifs (CG) pour c-Rel et RelB et lors de la différentiation en plasmocyte pour RelA. Le lymphome diffus à grandes cellules (DLBCL) représente plus de 80% des lymphomes B agressifs. Nous avons publié que les SU NF-kB doivent être prises en compte de façon différentielle, tel que RelB est un marqueur de mauvais pronostic, RelA est la SU du sous-type moléculaire ABC (activated B cell) et cRel ce
APA, Harvard, Vancouver, ISO, and other styles
2

Wu, Yen-Fei, and 吳彥霏. "The Role of Galectin-9 in Germinal Centre B-cell-like Diffuse Large B Cell Lymphoma (GCB-DLBCL)." Thesis, 2016. http://ndltd.ncl.edu.tw/handle/72125881113790583302.

Full text
Abstract:
碩士<br>國立臺灣大學<br>免疫學研究所<br>104<br>Galectin-9, a tandem-repeat type galectin, was first identified in patients with a nodular sclerosis type of Hodgkin’s disease. Previous studies demonstrated various regulatory roles of galectin-9 in the immune responses. However, role of galectin-9 in cancer biology remains elusive. Here, we found galectin-9 expression in germinal centre B-cell-like diffuse large B cell lymphoma (GCB DLBCLs) was up-regulated amongst germinal center lymphomas. To determine the role of elevated galectin-9 expression in vivo, we used NOD/SCID xenograft model of GCB DLBCLs. Striki
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Gcb-Dlbcl"

1

Abraham Jacob, Linu, and Animesh Gupta. "DLBCL Subtypes and Prognosis Based on Immunophenotyping." In Lymphoma - Recent Advances [Working Title]. IntechOpen, 2023. http://dx.doi.org/10.5772/intechopen.109216.

Full text
Abstract:
DLBCL is the most common type of NHL diagnosed in the world. It is a highly heterogeneous disease with variable prognosis and is generally managed with standard chemo-immunotherapy and its variations. Immunohistochemistry has been found to be useful method to both sub-classify and to predict prognosis of this disease. IHC utilises various CD markers like CD10, BCL2 and IRF4 to divide DLBCL into GCB and non-GCB subtype. In clinical trials, GCB subtype has been shown to have a better prognosis and a response to treatment when compared to non-GCB subtype. Double hit/double expressor is a newer va
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Gcb-Dlbcl"

1

Koning, Marvyn T., Rudolf Übelhart, Arjen H. G. Cleven, et al. "Abstract LB-012: Autonomous, antigen-independent B-cell receptor signalling as a novel pathogenetic mechanism in non-GCB DLBCL." In Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.am2016-lb-012.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Maerevoet, Marie, Jason Westin, Catherine Thieblemont, et al. "Abstract CT132: A Phase 2b randomized study of selinexor in patients with relapsed/refractory Diffuse Large B-Cell Lymphoma (DLBCL) demonstrates durable responses in both GCB & Non-GCB subtypes." In Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.am2017-ct132.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Lin, Xiaoyu, Xiaoli Huang, Aparna Sarthy, et al. "Abstract 4706: ABBV-075 exhibits robust in vitro and in vivo activities against the ABC and GCB subtypes of DLBCL." In Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.am2016-4706.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Kawagishi, Aki, Hiroki Irie, Yoshio Ogino, Hideya Komatani, and Teruhiro Utsugi. "Abstract A274: Novel SYK inhibitors have demonstrated potent antiproliferative effects in both ABC- and GCB-DLBCL cell lines via suppression of multiple pathways downstream of the B-cell receptor." In Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics--Oct 19-23, 2013; Boston, MA. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1535-7163.targ-13-a274.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Goi, Mariana Copetti, Ana Paula Santana de z. Abreu, Sheila Cristina Lordelo Wludarski, Joaquim Teodoro de Araújo Neto, and Edison Mantovani Barbosa. "Primary breast lymphoma associated with invasive breast carcinoma: a case report." In XXVI Brazilian Mastology Congress. Mastology, 2024. https://doi.org/10.29289/259453942024v34s2039.

Full text
Abstract:
Introduction: This case report describes a 54-year-old patient who developed invasive breast carcinoma in her left breast without further specifications, of the luminal B molecular subtype, concurrently with a primary breast lymphoma (diffuse large B-cell lymphoma with the germinal center B-cell subtype), which was definitively diagnosed only after surgical intervention. Synchronous occurrence of breast cancer and non-Hodgkin lymphoma (NHL) is an uncommon situation, with only 38 cases reported in the literature. It is extremely rare for both tumors to present as a collision tumor within the sa
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Gcb-Dlbcl' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography